(Q43868199)

English

A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial

scientific article published in December 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 November 2017

A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial (English)

1 reference

Europe PubMed Central

27 November 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

ocular hypertension

1 reference

based on heuristic

inferred from title

open-angle glaucoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

H B DuBiner

1

1 reference

Europe PubMed Central

27 November 2017

M Mroz

2

1 reference

Europe PubMed Central

27 November 2017

A M Shapiro

3

1 reference

Europe PubMed Central

27 November 2017

M S Dirks

4

1 reference

Europe PubMed Central

27 November 2017

Brimonidine vs. Latanoprost Study Group

5

1 reference

Europe PubMed Central

27 November 2017

publication date

1 December 2001

1 reference

Europe PubMed Central

27 November 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

27 November 2017

23

1 reference

Europe PubMed Central

27 November 2017

12

1 reference

Europe PubMed Central

27 November 2017

1969-1983

1 reference

Europe PubMed Central

27 November 2017

The role of medical therapy in the rank order of glaucoma treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological therapy for glaucoma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiglaucoma medications: a review of safety and tolerability issues related to their use.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of brimonidine on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost: experience of 2-year treatment in Scandinavia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost for uncontrolled glaucoma in a compassionate case protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience with latanoprost: a retrospective study of 153 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

CME and anterior uveitis with latanoprost use.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anterior uveitis associated with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980150-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(01)80150-8

1 reference

Europe PubMed Central

27 November 2017

1 reference

Europe PubMed Central

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43868199&oldid=2104037028"